Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward

  title={Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward},
  author={Daniel Wolfe and M Patrizia Carrieri and Donald S. Shepard},
  journal={The Lancet},

Figures from this paper

HIV Testing, Care, and Treatment Among Women Who Use Drugs From a Global Perspective: Progress and Challenges
Future success in enhancing the HIV continuum for women drug users should consider structural and contextual level barriers and promote social, economic, and legal policies that overhaul the many years of discrimination and stigmatization faced by womendrug users worldwide.
Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries
In order to be able to monitor the impact of HIV treatment and harm reduction services for PWID on the epidemic, epidemiological data on IDU and harm Reduction service provision to PWID needs to be regularly collected using standardised indicators.
Accessibility and integration of HIV, TB and harm reduction services for people who inject drugs in Portugal: a rapid assessment
The assessment documented two models of integrated HIV, TB and drug dependency care for PWID in Porto, Portugal, which facilitates multidisciplinary care but is resource-intensive, limited to a specific location and offers reduced scope for community/home-based care.
Barriers to antiretroviral treatment access for injecting drug users living with HIV in Chennai, South India
To facilitate IDUs gaining access to ART, systemic changes are needed, including steps to make the environment and procedures at government ART centers more IDU-friendly and steps to decrease HIV- and drug use-related stigma and discrimination faced by IDUs from the general public and health-care providers.
HIV prevention, treatment, and care for people who inject drugs.
This issue of the Journal presents the first study of mortality among Chinese methadone clients, with 2 key findings: earlier initiation of ART (at CD4+ T-cell counts >300/mm3) among HIV-positive clients was protective against death, and Methadone doses >75 mg/day were protective againstdeath for all clients, regardless of HIV status.
Human rights and access to hepatitis C treatment for people who inject drugs.


Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs and demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.
Antiretroviral therapy in Malaysia: identifying barriers to universal access
Increasing and improved access to ART for HIV-infected patients will entail a multipronged strategy that includes the decentralization of clinical care, increased and ongoing training of healthcare workers and support staff, and a comprehensive and intensive effort to reduce stigma and discrimination.
A review of barriers and facilitators of HIV treatment among injection drug users
Evidence demonstrates that several under-utilized interventions and novel antiretroviral delivery modalities have helped to greatly address barriers in several settings, and there is sufficient evidence to support immediate scale-up of these programmes.
Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5").
There is evidence that the coverage of ART among current/former IDUs is proportionally substantially less than other exposure categories, and ongoing monitoring of ART by exposure and population subgroups is critical to ensuring that scale-up is equitable, and that the distribution of ART is transparent.
Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
Logistic regression showed that, with respect to ex-IDUs and independently of clinical stage, active IDUs, whether or not they were perceived as such by physicians, were threefold more likely not to receive antiretroviral treatment.